The shifting impact and response to COVID-19 in Florida.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Rivkees SA;Rivkees SA
  • Source:
    Frontiers in public health [Front Public Health] 2024 Feb 19; Vol. 12, pp. 1351690. Date of Electronic Publication: 2024 Feb 19 (Print Publication: 2024).
  • Publication Type:
    Journal Article; Review
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet ISSN: 2296-2565 (Electronic) Linking ISSN: 22962565 NLM ISO Abbreviation: Front Public Health Subsets: MEDLINE
    • Publication Information:
      Original Publication: Lausanne : Frontiers Editorial Office
    • Subject Terms:
    • Abstract:
      The first cases of COVID-19 in Florida were diagnosed on March 1, 2020. Three years later, more than 7.3 million people have had COVID-19 in Florida, and more than 93,000 individuals have died from this illness. When considering the impact of COVID-19 on Florida, several key factors need to be considered, including that Florida was one of the most medically vulnerable states due to a substantial proportion of older individuals and those with underlying medical conditions. Florida also has a centralized Department of Health and Division of Emergency Management structure that facilitated response activities. Looking at the impact of COVID-19 on Florida, two distinct phases need to be considered: the pre-Delta variant phase from March 2020 to July 2021 and the Delta variant and beyond phase that began July 2021 and still continues. During the 16-month first phase, about 38,000 people died. Yet, 24,000 people died during the 5-months of the Delta variant wave from July to November 2021. During the Omicron waves that followed Delta, an additional 31,000 people died. Florida thus went from ranking 26th in death per capita in the United States at the end of the first phase to 10th a few months into the Delta wave and now ranks 8th. Why did these phases differ so dramatically in terms of mortality? During the first phase of the pandemic, adherence to established nonpharmacological and older adult protection measures was recommended. When COVID-19 vaccines became available in December 2020, there was an aggressive campaign to promote COVID-19 vaccination, and public acceptance was high. The second phase followed political opposition to CDC and public health expert guidelines, the rise of anti-vaccine sentiment and misinformation, and falling vaccination rates. These factors contributed to considerable population vulnerability to severe disease when the Delta variant hit. As the former State Surgeon General and Secretary of Health of Florida from June 2019 to September 2021, this report provides perspective on the shifting impact and response to COVID-19 in Florida, which is the third most populous state in the United States. This perspective shows the clear consequences of shifting from standard public health practices and vaccine promotion to attacks on public health and vaccines.
      Competing Interests: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
      (Copyright © 2024 Rivkees.)
    • References:
      Lancet Infect Dis. 2021 Nov;21(11):1493-1494. (PMID: 34627498)
      BMC Public Health. 2022 Oct 10;22(1):1882. (PMID: 36217102)
      N Engl J Med. 2020 Mar 5;382(10):929-936. (PMID: 32004427)
      Lancet. 2023 Apr 22;401(10385):1314-1315. (PMID: 37087157)
      Lancet. 2023 Apr 22;401(10385):1341-1360. (PMID: 36966780)
      Int J Infect Dis. 2022 Jul;120:142-145. (PMID: 35477053)
      MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):437-441. (PMID: 33764962)
      N Engl J Med. 2021 Aug 12;385(7):585-594. (PMID: 34289274)
      Sci Rep. 2022 Jan 31;12(1):1677. (PMID: 35102196)
      Public Health Rep. 2020 Sep/Oct;135(5):560-564. (PMID: 32758023)
      Biomed Pharmacother. 2024 Feb;171:116055. (PMID: 38171239)
      Lancet. 2023 Mar 11;401(10379):833-842. (PMID: 36930674)
      China CDC Wkly. 2020 Feb 21;2(8):113-122. (PMID: 34594836)
      MMWR Morb Mortal Wkly Rep. 2021 Jan 01;69(5152):1657-1660. (PMID: 33382671)
    • Contributed Indexing:
      Keywords: COVID-19; Florida; pandemic; policy; public health; vaccine
    • Accession Number:
      0 (COVID-19 Vaccines)
    • Subject Terms:
      SARS-CoV-2 variants
    • Publication Date:
      Date Created: 20240305 Date Completed: 20240306 Latest Revision: 20240513
    • Publication Date:
      20240513
    • Accession Number:
      PMC10909809
    • Accession Number:
      10.3389/fpubh.2024.1351690
    • Accession Number:
      38439756